Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients Receiving Vincristine through Push Injections or One-Hour Infusions: Results of a Randomized Clinical Trial

Mirjam Esther Van De Velde, MD, Gertjan Johannes Laurentius Kaspers, Prof. MD PhD, Floor Abbink, MD, Marry M. van den Heuvel-Eibrink, Prof, MD PhD, Cor van den Bos, MD PhD, Inge M. van der Sluis, MD PhD, Heidi Segers, MD PhD, Leen Willems, MD PhD, Jutte Van Der Werff, Prof, MD PhD, Christophe Chantrain, MD PhD, Machteld Heleen van den Berg, PhD

Blood (2019) 134 (Supplement_1): 1350.

https://doi.org/10.1182/blood-2019-126532

Published: 2019

Journal Articles

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Laura L Hester, PhD MSc, Dina M Gifkins, PhD MPH, Kevin M Bellew, MS, MA, Jessica Vermeulen, MD PhD, Jordan M Schecter, MD, Frank J DeFalco, Brendan M Weiss, MD

Blood (2019) 134 (Supplement_1): 5517.

https://doi.org/10.1182/blood-2019-124250

Published: 2019

Journal Articles

Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Shijia Zhang, MD PhD, Yucai Wang, MD, Yvonne Datta, MD, Veronika Bachanova, MD PhD, Sarah Cooley, MD

Blood (2018) 132 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2018-99-113533

Published: 2018

Journal Articles

Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma

Mirjam Esther Velde, MD MSc, Machteld Heleen van den Berg, PhD, Floor Abbink, MD, Heidi Segers, MD PhD, Barbara De Moerloose, MD PhD, Marry M. van den Heuvel-Eibrink, Prof, Cor van den Bos, MD PhD, Inge M. van der Sluis, MD PhD, Gertjan Johannes Laurentius Kaspers, MD PhD

Blood (2018) 132 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2018-99-115905

Published: 2018

Journal Articles

Neurological Adverse Events Determine Morbidity and Mortality Post Allogeneic Hematopoietic Cell Transplantation

Ioanna Sakellari, Eleni Gavriilaki, MD, Sotirios Papagiannopoulos, Maria Gavriilaki, MD, Ioannis Batsis, Despina Mallouri, Anna Vardi, MD PhD, Varnavas Constantinou, Michalis Iskas, Marianna Masmanidou, Evangelia Yannaki, MD, Triantafyllos Geroukis, MD, Dimitrios Kazis, Vasilis Kimiskidis, Achilles Anagnostopoulos

Blood (2018) 132 (Supplement 1): 5732.

https://doi.org/10.1182/blood-2018-99-112032

Published: 2018

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience

Ja Min Byun, Jeong-Ok Lee, Tae Min Kim, MD PhD, Bhumsuk Keam, Dae Seog Heo, Ki Hwan Kim, Soo-Mee Bang, Jong Seok Lee

Blood (2016) 128 (22): 4222.

https://doi.org/10.1182/blood.V128.22.4222.4222

Published: 2016

Journal Articles

Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study

Xavier Leleu, Maria-Victoria Mateos, Michel Delforge, Philip Lewis, Thomas Schindler, Craig Gibson, Min Yang, Katja C. Weisel

Blood (2015) 126 (23): 2086.

https://doi.org/10.1182/blood.V126.23.2086.2086

Published: 2015

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

Philippe Moreau, MD, Thierry Facon, MD, Cyrille Touzeau, MD, Lotfi Benboubker, MD, Martine Delain, MD, Julie Badamo-Dotzis, PhD, Charles Phelps, Christopher Doty, Hans Smit, PhD, Nele Fourneau, MD, Ann Forslund, Peter Hellemans, MD, Xavier Leleu, MD, PhD

Blood (2013) 122 (21): 1932.

https://doi.org/10.1182/blood.V122.21.1932.1932

Published: 2013

Journal Articles

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Noopur Raje, MD, Edward Anthony Faber, Jr., DO, MS, Paul G. Richardson, MD, Gary J. Schiller, MD, Raymond J. Hohl, MD, PhD, Adam D. Cohen, MD, Andres Forero, MD, Susan P. Carpenter, PhD, Damien Cronier, PhD, Christopher Kaiser, PhD, James E. Wooldridge, MD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 447.

https://doi.org/10.1182/blood.V120.21.447.447

Published: 2012

Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2012) 120 (21): 4065.

https://doi.org/10.1182/blood.V120.21.4065.4065

Published: 2012

Journal Articles

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Yongqian Jia, MD, Bing Xiang, MD, Xiaodong Wang, MD, Jianjun Li, MD, Chuan He, MD, Yi Su, MD, Hong Lu, MD, Ting Niu, MD, Jie Huang, MD, Xinchuan Chen, MD, Xu Cui, MD, Yuping Gong, MD, PhD, Huanling Zhu, MD, Ting Liu, MD

Blood (2011) 118 (21): 3714.

https://doi.org/10.1182/blood.V118.21.3714.3714

Published: 2011

Journal Articles

Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.

Deborah S Ricci, Reyna Favis, Yu Sun, Helgi van de Velde, Erin Broderick, Michael Meyers, Jean-Luc Harousseau, Hervé Avet-Loiseau, Paul G Richardson, Jesús F San Miguel

Blood (2009) 114 (22): 3875.

https://doi.org/10.1182/blood.V114.22.3875.3875

Published: 2009

Journal Articles

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Irene M Ghobrial, Nikhil C Munshi, Brianna N Harris, Zheng Yuan, Nichole M Porter, Robert L Schlossman, Jacob P Laubach, Kenneth C. Anderson, Courtney E Lin, James E Wooldridge, Paul G Richardson, Rafat Abonour

Blood (2009) 114 (22): 1870.

https://doi.org/10.1182/blood.V114.22.1870.1870

Published: 2009

Journal Articles

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Wendy Stock, MD, Leonard Heffner, MD, Alexandra Tredinnick, Baio Lu, Gavin S. Choy, Steven R. Deitcher, MD, Susan M. O’Brien, MD

Blood (2007) 110 (11): 858.

https://doi.org/10.1182/blood.V110.11.858.858

Published: 2007

Journal Articles

The Treatment of Delayed Rejection after Boosting of Mononuclear Cells of Her Mother and Chronic Graft Versus Host Disease in Leukemia Recipient Who Underwent Allogeneic Hyplo-Identical Transplantation in Second Remission with Therapeutic Plasma Exchange.

Zhisheng Jiang, MD, Da Li, MD, Shunjie Wu, MD, Kun Liu, MD, Ying Kang, MD, Gi Chen, MD, Xinghao Lan, MD, Suiquan Chen, MD, Wei Yi, MD

Blood (2006) 108 (11): 5237.

https://doi.org/10.1182/blood.V108.11.5237.5237

Published: 2006

NARROW

Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients Receiving Vincristine through Push Injections or One-Hour Infusions: Results of a Randomized Clinical Trial

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma

Neurological Adverse Events Determine Morbidity and Mortality Post Allogeneic Hematopoietic Cell Transplantation

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience

Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Phase 1b Dose Escalation Study Of Oral Quisinostat, a Histone Deacetylase Inhibitor (HDACi), In Combination With Velcade (Bortezomib) and Dexamethasone For Patients With Relapsed Multiple Myeloma (MM)

Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

The Treatment of Delayed Rejection after Boosting of Mononuclear Cells of Her Mother and Chronic Graft Versus Host Disease in Leukemia Recipient Who Underwent Allogeneic Hyplo-Identical Transplantation in Second Remission with Therapeutic Plasma Exchange.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only